Search

Your search keyword '"Kogure, Yuki"' showing total 21 results
Start Over Author "Kogure, Yuki"
21 results on '"Kogure, Yuki"'

1. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Author

Tsuji, Daiki, Nakagaki, Shigeru, Yonezawa, Itsuki, Suzuki, Kenichi, Yokokawa, Takashi, Kawasaki, Yohei, Yamaguchi, Takumi, Kawaguchi, Takashi, Hatori, Masahiro, Matsumoto, Takuma, Sakata, Yukio, Yamamoto, Keisuke, Nishimura, Tomoyasu, Kogure, Yuki, Hayashi, Toshinobu, Osawa, Misa, Itoh, Kunihiko, and Watanabe, Masaya

Published
2024
Full Text
View/download PDF

2. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Author

Hatori, Masahiro, Tsuji, Daiki, Suzuki, Kenichi, Yokokawa, Takashi, Kawakami, Kazuyoshi, Moriyama, Ryo, Osada‐Tsuchiya, Marika, Otake, Aki, Nakao, Masahiko, Yano, Takuya, Arakawa, Yuichiro, Matsuo, Keisuke, Ohashi, Yasukata, Sakata, Yasuhiko, Kogure, Yuki, Tamaki, Shinya, Wada, Atsushi, Taki, Yusuke, Sasahira, Naoki, and Ishii, Hiroshi

Subjects
SOMATIC mutation, GENETIC polymorphisms, RIBONUCLEOSIDE diphosphate reductase, LOGISTIC regression analysis
Abstract

Background: Genetic polymorphisms of molecules are known to cause individual differences in the therapeutic efficacy of anticancer drugs. However, to date, germline mutations (but not somatic mutations) for anticancer drugs have not been adequately studied. The objective of this study was to investigate the association between germline polymorphisms of gemcitabine metabolic and transporter genes with carbohydrate antigen 19‐9 (CA 19‐9) response (decrease ≥50% from the pretreatment level at 8 weeks) and overall survival (OS) in patients with metastatic pancreatic cancer who receive gemcitabine‐based chemotherapy. Methods: This multicenter, prospective, observational study enrolled patients with metastatic pancreatic cancer patients who were receiving gemcitabine monotherapy or gemcitabine plus nanoparticle albumin‐bound paclitaxel combination chemotherapy. Thirteen polymorphisms that may be involved in gemcitabine responsiveness were genotyped, and univariate and multivariate logistic regression analyses were used to determine the association of these genotypes with CA 19‐9 response and OS. The significance level was set at 5%. Results: In total, 180 patients from 11 hospitals in Japan were registered, and 159 patients whose CA 19‐9 response could be assessed were included in the final analysis. Patients who had a CA 19‐9 response had significantly longer OS (372 vs. 241 days; p =.007). RRM1 2464A>G and RRM2 175T>G polymorphisms suggested a weak association with CA 19‐9 response and OS, but it was not statistically significant. COX‐2 −765G>C polymorphism did not significantly correlate with CA 19‐9 response but was significantly associated with OS (hazard ratio, 2.031; p =.019). Conclusions: Genetic polymorphisms from the pharmacokinetics of gemcitabine did not indicate a significant association with efficacy, but COX‐2 polymorphisms involved in tumor cell proliferation might affect OS. This study investigated the association between germline polymorphisms of gemcitabine metabolic and transporter genes and carbohydrate 19‐9 response and overall survival in patients with metastatic pancreatic cancer who were receiving gemcitabine‐based chemotherapy. Germline polymorphisms of the metabolic pathway and transporter genes in gemcitabine were not significantly associated with efficacy, but COX‐2 polymorphisms were associated with overall survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Pharmacogenomic study of gemcitabine on the safety and efficacy in patients with metastatic pancreatic cancer (GENESECT study): Analysis of a subpopulation.

Author

Yokokawa, Takashi, primary, Tsuji, Daiki, additional, Hatori, Masahiro, additional, Suzuki, Kenichi, additional, Kawakami, Kazuyoshi, additional, Nakao, Masahiko, additional, Yano, Takuya, additional, Arakawa, Yuichiro, additional, Matsuo, Keisuke, additional, Ohashi, Yasukata, additional, Ozaka, Masato, additional, Sasahira, Naoki, additional, Sakata, Yasuhiko, additional, Kogure, Yuki, additional, Tamaki, Shinya, additional, Wada, Atsushi, additional, Taki, Yusuke, additional, Ishii, Hiroshi, additional, Itoh, Kunihiko, additional, and Yamaguchi, Masakazu, additional

Published
2024
Full Text
View/download PDF

5. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Author

Tsuji, Daiki, primary, Nakagaki, Shigeru, additional, Yonezawa, Itsuki, additional, Suzuki, Kenichi, additional, Yokokawa, Takashi, additional, Kawasaki, Yohei, additional, Yamaguchi, Takumi, additional, Kawaguchi, Takashi, additional, Hatori, Masahiro, additional, Matsumoto, Takuma, additional, Sakata, Yukio, additional, Yamamoto, Keisuke, additional, Nishimura, Tomoyasu, additional, Kogure, Yuki, additional, Hayashi, Toshinobu, additional, Osawa, Misa, additional, Itoh, Kunihiko, additional, and Watanabe, Masaya, additional

Published
2023
Full Text
View/download PDF

6. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

Author

Matsui, Reiko, Suzuki, Kenichi, Takiguchi, Tomomi, Nishio, Makoto, Koike, Takeshi, Hayashi, Toshinobu, Seto, Takashi, Kogure, Yuki, Nogami, Naoyuki, Fujiwara, Kimiko, Kaneda, Hiroyasu, Harada, Tomohiko, Shimizu, Satoru, Kimura, Masashi, Kenmotsu, Hirotsugu, Shimokawa, Mototsugu, and Goto, Koichi

Published
2020
Full Text
View/download PDF

11. 5-Hydroxytryptamine-3 Receptor Antagonist and Dexamethasone as Prophylaxis for Chemotherapy Induced Nausea and Vomiting during Moderately Emetic Chemotherapy for Solid Tumors: A Multicenter, Prospective, Observational Study

Author

Matsui, Reiko, primary, Suzuki, Kenichi, additional, Takiguchi, Tomomi, additional, Nishio, Makoto, additional, Koike, Takeshi, additional, Hayashi, Toshinobu, additional, Seto, Takashi, additional, Kogure, Yuki, additional, Nogami, Naoyuki, additional, Fujiwara, Kimiko, additional, Kaneda, Hiroyasu, additional, Harada, Tomohiko, additional, Shimizu, Satoru, additional, Kimura, Masashi, additional, Kenmotsu, Hirotsugu, additional, Shimokawa, Mototsugu, additional, and Goto, Koichi, additional

Published
2020
Full Text
View/download PDF

13. Nb-based superconducting tunnel junctions with [beta]-Ta trapping layers for phonon detection

Author

Myoren, Hiroaki, Kogure, Yuki, Takada, Susumu, Sato, Hiromi, Otani, Chiko, Shimizu, Hirohiko M., and Maehata, Keisuke

Subjects
Superconductive devices -- Research, Detectors -- Research, Phonons -- Research, Business, Electronics, Electronics and electrical industries
Abstract

Fabrication of Nb-based suerconducting tunnel junctions (STJ) with [beta]-Ta trapping layers is described and discussed.

Published
2003

15. Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.

Author

Ayuhara, Hideaki, primary, Tsuji, Daiki, additional, Yokoi, Mari, additional, Suzuki, Kenichi, additional, Kawasaki, Yohei, additional, Nakao, Masahiko, additional, Kogure, Yuki, additional, Shibata, Kazuhiko, additional, Hayashi, Toshinobu, additional, Hirai, Keita, additional, Inoue, Kazuyuki, additional, Hama, Toshihiro, additional, Takeda, Koji, additional, Nishio, Makoto, additional, and Itoh, Kunihiko, additional

Published
2017
Full Text
View/download PDF

16. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin.

Author

Hashimoto, Hironobu, primary, Yanai, Takako, additional, Nagashima, Kengo, additional, Tsuda, Natsuko Okita, additional, Horinouchi, Hidehito, additional, Takiguchi, Tomomi, additional, Ohyanagi, Fumiyoshi, additional, Nakao, Masahiko, additional, Takeda, Koji, additional, Nakayama, Toshiaki, additional, Sakai, Hiroshi, additional, Arai, Takahiro, additional, Minato, Koichi, additional, Kogure, Yuki, additional, Harada, Daijiro, additional, Suzuki, Kenichi, additional, Boku, Narikazu, additional, Shimada, Yasuhiro, additional, Iwasa, Satoru, additional, and Yamamoto, Noboru, additional

Published
2016
Full Text
View/download PDF

18. Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.

Author

Hashimoto, Hironobu, primary, Yamanaka, Takeharu, additional, Shimada, Yasuhiro, additional, Arata, Koji, additional, Matsui, Reiko, additional, Goto, Koichi, additional, Takiguchi, Tomomi, additional, Ohyanagi, Fumiyoshi, additional, Kogure, Yuki, additional, Nogami, Naoyuki, additional, Nakao, Masahiko, additional, Takeda, Koji, additional, Azuma, Kanako, additional, Nagase, Seisuke, additional, Hayashi, Toshinobu, additional, Fujiwara, Kimiko, additional, Shimada, Toshikazu, additional, Seki, Nobuhiko, additional, Suzuki, Kenichi, additional, and Yamamoto, Nobuyuki, additional

Published
2013
Full Text
View/download PDF

21. Nb-Based Superconducting Tunnel Junctions With β-Ta Trapping Layers for Photon Detectors.

Author

Myoren, Hiroaki, Kogure, Yuki, Takada, Susumu, Sato, Hiromi, Otani, Chiko, Shimizu, Hirohiko M., and Maehata, Keisuke

Subjects
*PHOTON detectors, *SUPERCONDUCTORS, *QUANTUM tunneling, *TANTALUM
Abstract

We have successfully fabricated Nb-based superconducting tunnel junctions (STJs) with β-Ta trapping layers. In an Nb/ β-Ta stacked structure, β-Ta film showed the thickness dependence of critical temperature T[sub c] in current-voltage (I-V) characteristics due to the proximity effect from Nb films. We fabricated Nb-based STJs with Β-Ta trapping layers for X-ray detector working at 0.4 K. We obtained an energy resolution of 52 eV for 5.9 kev X-ray irradiation at 0.4 K. We expect a high energy resolution by optimizing the thickness of Β-Ta trapping layers and improving the fabrication process. [ABSTRACT FROM AUTHOR]

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results